Medication topics
Ozanimod articles covering Zeposia, S1P-modulator therapy, safety, approvals, access, and IBD treatment decisions. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
11 articles
This registry study offers real-world data on ozanimod effectiveness, persistence, and safety in UC patients, which can help patients and clinicians set expectations beyond clinical trial settings.
This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...
Older adults with IBD are under-represented in trials, so age-specific benefits and harms of newer oral drugs (JAK inhibitors and S1P modulators) are uncertain. Clinicians and patients may need to weigh efficacy against...
The study provides real-world data on ozanimod effectiveness, safety, and how prior biologic exposure (notably vedolizumab) may affect treatment persistence—information relevant for treatment planning in UC.
Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...
S1P receptor modulators are an emerging oral class of advanced therapy for moderate-to-severe ulcerative colitis; a systematic review that pools multiple RCTs helps clarify how effective and safe the class appears to be...
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...
This trial explores whether oral ozanimod can induce and maintain remission in children and adolescents with moderate to severe ulcerative colitis who have not responded to standard therapies. Pediatric-specific evidence...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
New approvals and pipeline activity can expand future treatment options and affect availability, pricing, and research priorities for Crohn’s disease. Market analyses can signal which therapies companies expect to...
The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...
